| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Dlin-MeOH is a lipid and does not have a specific biological receptor target. It is used as a component in lipid nanoparticles (LNPs) to facilitate the delivery of therapeutic agents, such as genetic material, into cells. Its role is to enhance the stability and cellular uptake of drug delivery systems.
|
|---|---|
| ln Vitro |
Dlin-MeOH is used in vitro as a component of lipid-based drug delivery systems. It is incorporated into liposomes or LNPs to improve their stability and facilitate cellular uptake. It is used in cell culture studies to evaluate the delivery and efficacy of encapsulated drugs or nucleic acids.
|
| ln Vivo |
In vivo, Dlin-MeOH is used in lipid nanoparticle formulations for the delivery of therapeutic agents. LNPs containing Dlin-MeOH are administered intravenously to deliver drugs or genetic material to target tissues. It is used in non-viral gene therapy to facilitate the transport of genetic material while minimizing immune responses.
|
| Enzyme Assay |
In vitro, LNPs are formulated using Dlin-MeOH, cholesterol, helper lipids, and PEG-lipids. The lipids are dissolved in ethanol and mixed with nucleic acids in an aqueous buffer to form LNPs. The resulting LNPs are characterized for size, polydispersity, and encapsulation efficiency. Cells are then treated with the LNPs, and delivery and efficacy are assessed.
|
| Cell Assay |
In cell-based assays, LNPs containing Dlin-MeOH are added to cell cultures. Cellular uptake of the LNPs and the delivery of encapsulated cargo (e.g., mRNA, siRNA) are measured. The compound's ability to facilitate gene delivery is assessed by measuring gene expression or knockdown.
|
| Animal Protocol |
In vivo, LNPs formulated with Dlin-MeOH are administered to animals via intravenous injection. The animals are monitored for the expression of the delivered nucleic acid, therapeutic efficacy, and potential toxicity. The LNPs facilitate the delivery of nucleic acids to target tissues, such as the liver.
|
| ADME/Pharmacokinetics |
Dlin-MeOH has a molecular weight of 528.94 and formula C37H68O. It is a colorless to light yellow liquid. It is soluble in organic solvents such as DMSO. Storage: -20°C.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Dlin-MeOH are not extensively documented. As a lipid component, its toxicity is typically evaluated as part of the LNP formulation. The compound is for research use only. It should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
Dlin-MeOH is also known as 1,2-dilinoleoyl-sn-glycero-3-methanol. It is a lipid product used in active molecule delivery systems. It is commonly used in non-viral gene therapy.
|
| Molecular Formula |
C37H68O
|
|---|---|
| Molecular Weight |
528.935232162476
|
| Exact Mass |
528.527
|
| CAS # |
1169768-28-8
|
| PubChem CID |
44468963
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
15.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
38
|
| Complexity |
493
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCCC(O)CCCCCCCC/C=C\C/C=C\CCCCC
|
| InChi Key |
MXYDYSQZZPJVJD-MAZCIEHSSA-N
|
| InChi Code |
InChI=1S/C37H68O/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37(38)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,37-38H,3-10,15-16,21-36H2,1-2H3/b13-11-,14-12-,19-17-,20-18-
|
| Chemical Name |
(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~189.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8906 mL | 9.4529 mL | 18.9057 mL | |
| 5 mM | 0.3781 mL | 1.8906 mL | 3.7811 mL | |
| 10 mM | 0.1891 mL | 0.9453 mL | 1.8906 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
